The Annual Congress of the European Hematology Association (EHA)

Identifying Optimal Immunochemotherapy for Patients With Mantle Cell Lymphoma

Publish Date June 17, 2020

Few population-based studies have compared treatment approaches in the setting of mantle cell lymphoma.

Addition of Venetoclax to Azacitidine Associated With Clinically Significant OS Benefit in AML

Publish Date June 17, 2020

The addition of venetoclax to azacitidine was associated with a 34% reduction in risk of death.

Addition of Isatuximab to Kd Deepens Responses and Extends PFS in R/R Multiple Myeloma

Publish Date June 17, 2020

The majority of patients enrolled in this phase 3 trial had previously received both a proteasome inhibitor and an immunomodulatory agent.

Ropeginterferon Appears to Improve Polycythemia Vera Symptoms

Publish Date June 15, 2020

The purpose of this study was to determine if a cytoreductive agent could provide additional efficacy to treat blood hyperviscosity.

FLT3-ITD With an Insertion Site in the Beta1-Sheet Prognostic for Poor Outcomes in AML

Publish Date June 15, 2020

Among adult patients with newly diagnosed AML, the presence of an FLT3-ITD mutation with an insertion site in the beta1-sheet was associated shorter survival.

Ixazomib Found Effective as a Maintenance Therapy in Patients With Newly Diagnosed MM Who Are Ineligible for Transplant

Publish Date June 13, 2020

Ixazomib maintenance therapy prolonged PFS compared with placebo among patients with newly diagnosed MM who were not eligible for transplant.

Characteristics of Ruxolitinib Discontinuation Syndrome in Myelofibrosis

Publish Date June 13, 2020

Ruxolitinib discontinuation syndrome was associated with spleen length and platelet count, although severe cases were rare in a cohort of patients with myelofibrosis.

Overall Survival Improved After Fewer Chemotherapy Cycles in Advanced Hodgkin Lymphoma: Long-Term Follow-Up of GHSG HD18 Trial

Publish Date June 13, 2020

Researchers presented findings of a significantly higher 5-year OS rate in patients who received 4 cycles of eBEACOPP compared with patients who received 6/8 cycles.

Real World Evidence Shows OS Improvements in Older Patients With AML From 2000 to 2016

Publish Date June 13, 2020

A population-based study included nearly 4000 patients diagnosed with AML from 2000 to 2016 in Denmark.

Timing of MD-MTX Prophylaxis for DLBCL CNS Relapse Evaluated

Publish Date June 12, 2020

Administering MD-MTX prophylaxis against CNS relapse of DLBCL appeared best as early as possible or following R-CHOP completion.

Study Provides Support for TKI Discontinuation in Some Patients With CML

Publish Date June 12, 2020

This population-based study of patients with chronic phase CML evaluated the BCR/ABL1 TKI discontinuation rates for patients treated on and off a clinical trial.

Treatment Modifications Common Among Older Patients With cHL

Publish Date June 12, 2020

Modifications of ABVD or CHOP were common among elderly patients with cHL and may contribute to their disproportionate excess mortality, signaling a need for less toxic regimens.

Chemotherapy-Free Regimen Consisting of 3 Novel Agents for Previously Untreated, Poor Prognosis CLL

Publish Date June 12, 2020

In this study, obinutuzumab, ibrutinib, and venoclax were administered as first-line therapy in patients with CLL characterized by del(17p) and/or TP53 mutation.

All Oral Proteasome Inhibitor-Containing Regimen in Transplant-Ineligible Multiple Myeloma

Publish Date June 12, 2020

Ixazomib, lenalidomide, and dexamethasone are all oral agents and each one has been approved by the FDA in the setting of multiple myeloma.

Venetoclax Plus Low-Dose Cytarabine Improved OS in Untreated AML Ineligible for Intense Chemotherapy

Publish Date June 12, 2020

In an updated analysis, venetoclax plus low-dose cytarabine improved OS compared with placebo among patients with untreated AML who were ineligible for intense chemotherapy.

Inotuzumab Ozogamicin Plus R-CVP for Patients With DLBCL Who Are Ineligible for R-CHOP

Publish Date June 12, 2020

Inotuzumab ozogamicin instead of gemcitabine added to R-CVP did not improve OS or PFS, but less toxicity among patients with untreated DLBCL with comorbid conditions.

Dasatinib-Containing Induction Therapy Associated With High Rates of Allogeneic HSCT in Newly Diagnosed Ph+ ALL

Publish Date June 12, 2020

This analysis focused on the allo-HSCT-related end points in a study of patients with newly diagnosed Ph+ ALL treated with a 2-step dasatinib-containing induction regimen.